Long-term effects of ADS-5102 (amantadine) extended release capsules on OFF symptoms in Parkinson’s disease patients with levodopa-induced dyskinesia: Analysis of EASE LID 2 trial
Objective: Evaluate the long-term effect of ADS-5102 on OFF time among Parkinson’s disease (PD) patients with levodopa-induced dyskinesia (LID). Background: ADS-5102, the only drug FDA-approved…Levodopa and dopamine agonists dosage changes after Opicapone introduction
Objective: We aim to analyze changes in levodopa and dopamine agonists (DA) dosage after introduction of opicapone (OPC) in a daily clinical practice setting. Background:…Motor subtype change between OFF and ON periods in patients with Parkinson’s disease
Objective: To identify if there is any difference in the motor subtype of PwPD between "off" stage and "on" stage. Background: Patients with Parkinson’s disease…Efficacy and tolerability of opicapone in Parkinson´s disease in usual clinical practice
Objective: To evaluate the efficacy and tolerability of opicapone in usual clinical practice in patients with Parkinson's disease (PD). Background: Opicapone is a recently approved…Gastrointestinal symptoms as a risk factor for the appearance of motor fluctuations in patients with advanced Parkinson disease
Objective: Gastrointestinal alterations in patients with Parkinson`s Disease (EP) provoke alterations in the absorption of levodopa that facilitates the development of motor fluctuations. Study the…Safinamide: real world evidence in Toledo´s Movement Disorders Unit
Objective: We present a prospective observational-real life study about the use of safinamide in Movement Disorders Unit´s patients. Background: The gold standard of pharmacological treatment…The Efficacy and Safety of Subcutaneous Apomorphine in Patients with Parkinson’s Disease: A Meta-Analysis Randomized Controlled Trials
Objective: The objective of this study to evaluate the efficacy and safety of subcutaneous apomorphine for patients with Parkinson’s disease (PD). Background: Subcutaneous apomorphine has…Non motor fluctuations in Parkinson’s disease: Findings from a Tunisian cohort
Objective: To evaluate the frequency of non motor fluctuations (NMF) in Parkinson's disease (PD), their correlation with motor complications and their impact on the quality…Freezing of Gait in Parkinson’s Disease: Risk Factors and Associated Nonmotor Symptoms
Objective: To clarify risk factors for, and clinical associations of, freezing of gait (FOG) in Parkinson's disease (PD). Background: FOG is a disabling and incompletely…Efficacy and safety of the 5-Hydroxytryptophan on Levodopa-Induced Motor Complications in Parkinson’s disease.
Objective: To evaluate the efficacy of the 5-Hydroxytryptophan (5-HTP) on levodopa-induced motor complications in patients with Parkinson's disease (PD). Background: Several studies have indicated that…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 24
- Next Page »